Bruce Acken
About Bruce Acken
Bruce Acken is a Senior Principal Investigator at Bristol-Myers Squibb with over 30 years of experience in the pharmaceutical industry, specializing in analytical sciences and pharmaceutical analytical chemistry.
Current Role at Bristol-Myers Squibb
Bruce Acken is currently serving as a Senior Principal Investigator at Bristol-Myers Squibb in Summit, NJ. In this role, he focuses on high-level research and investigative projects relevant to the pharmaceutical industry. His work contributes towards the development and optimization of new drug formulations and therapeutic solutions.
Previous Experience at Fresenius Kabi USA
From 2014 to 2018, Bruce Acken was the Vice President at Fresenius Kabi USA, located in Skokie, IL. During his tenure, he played a pivotal role in overseeing various aspects of the company's pharmaceutical operations, including strategic planning, research, and development.
Leadership Roles at Merck
Bruce Acken has held significant leadership positions at Merck. From 2010 to 2013, he worked as the Executive Director, Analytical Sciences in Summit, NJ. Prior to this, he was the Executive Director of Pharmaceutical Analytical Chemistry from 2007 to 2010 in West Point, PA. In these roles, he specialized in analytical sciences, contributing to the enhancement of Merck's pharmaceutical research capabilities.
Educational Background in Chemistry
Bruce Acken achieved a Doctor of Philosophy (Ph.D.) in Chemistry from Georgetown University, where he studied from 1982 to 1987. He also holds a Bachelor of Science (B.S.) in Chemistry from Albright College, completed from 1979 to 1983. His extensive academic background laid the foundation for his career in the pharmaceutical industry.
Industry Experience and Specializations
With over 30 years of experience in the pharmaceutical industry, Bruce Acken has held senior leadership roles at major companies such as Merck, sanofi-aventis, and Pfizer. He specializes in analytical sciences and pharmaceutical analytical chemistry, contributing to formulation research and development, as well as biopharmaceutics during his tenure at A.H. Robins Company.